G protein-coupled receptor

CB1 receptor

Cannabinoid receptor 1

The CB1 receptor is a G protein-coupled receptor for cannabinoids. The human receptor was cloned from brain stem tissue and is 97 percent identical to the rat receptor. Its messenger RNA is abundant in the brain and present at lower levels in the testis.1 A review of the endocannabinoid system describes CB1 and CB2 as the two G protein-coupled receptors that mediate many of the effects of cannabinoids. CB1 receptors are present at very high levels in several brain regions and in lower amounts in a more widespread fashion, and they mediate many of the psychoactive effects of cannabinoids. Both receptors couple primarily to inhibitory G proteins.2 THC and the synthetic agonist CP 55,940 bind CB1 and CB2 about equally well. CB1 inhibits the formation of cyclic AMP, and in addition it inhibits Q-type calcium channels and opens inwardly rectifying potassium channels.3

In the brains of several mammals, humans included, it is densest in the outflow nuclei of the basal ganglia (substantia nigra pars reticulata and globus pallidus), in the hippocampus and in the cerebellum. It is sparse in the lower brainstem areas that control breathing and the heart, which may explain why high doses of THC are not lethal.4 Autoradiography showed that CB1 receptors are expressed at high levels in the brain regions expected from the psychoactive effects of THC, and at low levels in regions unaffected by cannabinoids, such as the respiratory centres of the medulla. They are expressed more abundantly than most other G protein-coupled receptors, and combined with in situ hybridisation the work suggested that they might be concentrated on axon terminals.2 The brain makes a substance that binds the receptor: anandamide (arachidonylethanolamide) was isolated from pig brain, and in a mouse tissue test it acted like the psychotropic cannabinoids.5

Mice without CB1 do not respond to cannabinoids, with no pain relief, reward, fall in body temperature, slowed movement or fall in blood pressure. In them morphine is also less rewarding, and withdrawal from it is milder.6 In another knockout strain, the mice appeared healthy and fertile, but had a significantly increased mortality rate. They showed reduced locomotor activity, increased ring catalepsy and hypoalgesia in the hotplate and formalin tests. THC-induced ring catalepsy, hypomobility and hypothermia were completely absent, while THC-induced analgesia in the tail-flick test and some other responses, among them diarrhoea, were still seen. The authors conclude that most, but not all, central nervous system effects of THC are mediated by the CB1 receptor.7 In 63 healthy men who smoked cannabis, the CB1 blocker rimonabant (SR141716) reduced the high and the rise in heart rate in a dose-dependent way, without changing THC levels in the blood.8

Rimonabant, a CB1 blocker, was approved as a weight-loss drug. A meta-analysis of four double-blind trials with 4,105 participants found that 20 mg a day gave a 4.7 kg greater weight reduction after one year than placebo. It also caused significantly more adverse events and 1.4 times more serious adverse events. Patients given rimonabant were 2.5 times more likely to stop treatment because of depressive mood disorders and 3.0 times more likely to stop because of anxiety, although depressed mood was an exclusion criterion in the trials.9

A review of the adverse health effects of recreational marijuana use states that long-term use can lead to addiction. About 9 percent of those who experiment with marijuana become addicted, about 1 in 6 of those who start as teenagers, and 25 to 50 percent of those who smoke daily. Regular use is also associated with anxiety and depression, but causality has not been established. Marijuana is linked with psychosis, especially in people with a genetic vulnerability, and heavier use, higher potency and an earlier start can bring forward a first psychotic episode by 2 to 6 years, although it is difficult to establish causality in these studies.10

Cannabidiol acts on CB1 as a negative allosteric modulator: in cells it reduced the efficacy and potency of THC and of the endocannabinoid 2-AG.11

Sources (11)
  1. Gérard et al. 1991Gérard CM, Mollereau C, Vassart G, et al. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem J
  2. Mackie 2008Mackie K (2008) Cannabinoid receptors: where they are and what they do J Neuroendocrinol
  3. Felder et al. 1995Felder CC, Joyce KE, Briley EM, et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol Pharmacol
  4. Herkenham et al. 1990Herkenham M, Lynn AB, Little MD, et al. (1990) Cannabinoid receptor localization in brain Proc Natl Acad Sci U S A
  5. Devane et al. 1992Devane WA, Hanus L, Breuer A, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science
  6. Ledent et al. 1999Ledent C, Valverde O, Cossu G, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science
  7. Zimmer et al. 1999Zimmer A, Zimmer AM, Hohmann AG, et al. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci U S A
  8. Huestis et al. 2001Huestis MA, Gorelick DA, Heishman SJ, et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch Gen Psychiatry
  9. Christensen et al. 2007Christensen R, Kristensen PK, Bartels EM, et al. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet
  10. Volkow et al. 2014Volkow ND, Baler RD, Compton WM, et al. (2014) Adverse health effects of marijuana use N Engl J Med
  11. Laprairie et al. 2015Laprairie RB, Bagher AM, Kelly ME, et al. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor Br J Pharmacol

Binding affinity (Kᵢ)

10 substances, 24 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

9 measurements

Mouse

8 measurements
  • CP 55,940Agonist0.30 nMGovaerts SophieJ et al. 2004
    Assay
    mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
  • HU-210Agonist0.32 nMGovaerts SophieJ et al. 2004
    Assay
    mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
  • JWH-018Agonist1.2 nMBrents et al. 2011
    Assay
    mouse whole-brain membrane homogenate containing CB1 receptors; [3H]CP-55,940 competition binding
    Shown value from
    Brents et al. 2011, Figure 2 and Results
  • WIN 55,212-2Agonist7.1 nMGovaerts SophieJ et al. 2004
    Assay
    mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
  • Δ⁹-THC (Tetrahydrocannabinol)Agonistother reports differ15 nMBrents et al. 2011 · 2 reports
    Assay
    mouse whole-brain membrane homogenate containing CB1 receptors; [3H]CP-55,940 competition binding
    Shown value from
    Brents et al. 2011, Figure 2 and Results
    Range
    15–98 nM in 2 reports

    This is the best-supported value. Other reports differ. 3 reports in all, 15–98 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Brents et al. 201115 nMFigure 2 and Results
    Govaerts SophieJ et al. 200498 nMTable 2
  • Δ⁸-THC (Tetrahydrocannabinol)Agonist123 nMGovaerts SophieJ et al. 2004
    Assay
    mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
  • Cannabidiol (CBD)Agonist259 nMLaprairie et al. 2015 · 3 reports
    Assay
    STHdhQ7/Q7 mouse striatal cells; operational model of allosterism, PLCβ3 phosphorylation, THC as orthosteric probe
    Shown value from
    Laprairie et al. 2015, Table 5
    Range
    259–329 nM in 3 reports
  • Cannabigerol (CBG)Agonistother reports differ381 nMCascio et al. 2010
    Assay
    MF1 mouse whole-brain membranes; displacement of [3H]CP55940
    Shown value from
    Cascio et al. 2010, Figure 6 legend

    This is the best-supported value. Other reports differ. 3 reports in all, 33–381 nM.

Rat

6 measurements
  • HU-210Agonistdepends on assayrange incl. untraced0.23 nMHowlett et al. 1990 · 5 reports
    Assay
    Rat brain cortex membranes; [3H]CP-55,940 displacement
    Shown value from
    Howlett et al. 1990, Results, Fig. 4
    Range
    0.10–2.8 nM in 5 reports
    Error
    ± 0.03 SEM

    Values depend on the assay, species or conditions, and each is valid only for its own. 5 reports in all, 0.10–2.8 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Howlett et al. 19900.23 nMResults, Fig. 4
    Govaerts SophieJ et al. 20042.8 nMTable 2
    Rhee et al. 19970.19 nM, 0.10 nMTable 1
    Griffin et al. 19980.73 nMTable 2, column CB1 Ki
  • JWH-018Agonist9.0 nMAung et al. 2000
    Assay
    rat cerebral cortex P2 membrane homogenate; [3H]CP-55,940 competition binding
    Shown value from
    Aung et al. 2000, Table 1
  • CP 55,940Agonistrange incl. untraced38 nMGovaerts SophieJ et al. 2004 · 2 reports
    Assay
    rat cerebellum membranes, [3H]SR 141716A displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
    Range
    0.58–38 nM in 2 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Govaerts SophieJ et al. 200438 nMTable 2
    Griffin et al. 19980.58 nMTable 2, column CB1 Ki
  • Δ⁹-THC (Tetrahydrocannabinol)Agonistdepends on assayrange incl. untraced209 nMGovaerts SophieJ et al. 2004 · 4 reports
    Assay
    rat cerebellum membranes, [3H]SR 141716A displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
    Range
    41–209 nM in 4 reports

    Values depend on the assay, species or conditions, and each is valid only for its own. 4 reports in all, 41–209 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Govaerts SophieJ et al. 2004209 nMTable 2
    Rhee et al. 199767 nM, 80 nMTable 1
    Griffin et al. 199841 nMTable 2, column CB1 Ki
  • Cannabinol (CBN)Agonistrange incl. untraced211 nMRhee et al. 1997 · 3 reports
    Assay
    COS-7 cells transfected with rat CB1 cDNA, displacement of [3H]HU-243
    Shown value from
    Rhee et al. 1997, Table 1
    Range
    211–392 nM in 3 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Rhee et al. 1997392 nM, 211 nMTable 1
    Griffin et al. 1998308 nMTable 2, column CB1 Ki
  • WIN 55,212-2Agonistrange incl. untraced282 nMGovaerts SophieJ et al. 2004 · 2 reports
    Assay
    rat cerebellum membranes, [3H]SR 141716A displacement
    Shown value from
    Govaerts SophieJ et al. 2004, Table 2
    Range
    1.9–282 nM in 2 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Govaerts SophieJ et al. 2004282 nMTable 2
    Griffin et al. 19981.9 nMTable 2, column CB1 Ki

Unspecified

1 measurement
  • JWH-018Agonistsource not traced9.0 nMBanister et al. 2015
    Assay
    literature binding value as compiled in Table S8, original assay of Aung 2000 (Drug Alcohol Depend 60:133)
    Shown value from
    Banister et al. 2015, Table S8 (Supporting Information)

Functional potency (EC₅₀)

9 substances, 17 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

9 measurements
  • HU-210Agonist0.20 nMRyberg et al. 2007
    Assay
    HEK293 membranes expressing human CB1, [35S]GTPgammaS binding
    Shown value from
    Ryberg et al. 2007, Table 1
    Error
    ± 0.03 SEM, n = 5
    Emax
    91.0 ± 2.0%
  • CP 55,940Agonistdepends on assay7.7 nMZagzoog et al. 2020 · 2 reports
    Assay
    HitHunter CHO cells stably expressing human receptor; inhibition of forskolin-stimulated cAMP for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
    Shown value from
    Zagzoog et al. 2020, Table 2
    Range
    2.6–7.7 nM in 2 reports
    Emax
    100.0 ± 6.2%

    Values depend on the assay, species or conditions, and each is valid only for its own. 5 reports in all, 0.20–920 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Zagzoog et al. 20207.7 nMTable 2
    Ross et al. 19992.6 nMTable 2
  • WIN 55,212-2Agonist18 nMRyberg et al. 2007
    Assay
    HEK293 membranes expressing human CB1, [35S]GTPgammaS binding
    Shown value from
    Ryberg et al. 2007, Table 1
    Error
    ± 3.0 SEM, n = 5
    Emax
    101.0 ± 14.0%
  • JWH-018Agonistunresolved102 nMBanister et al. 2015
    Assay
    mouse AtT-20 cells stably expressing human CB1, FLIPR membrane-potential/GIRK assay
    Shown value from
    Banister et al. 2015, Table 1
    Emax
    107.0 ± 6.0%

    Reported values disagree and no value is established. 2 reports in all, 23–102 nM.

  • Cannabigerol (CBG)Agonist120 nMZagzoog et al. 2020
    Assay
    HitHunter CHO cells stably expressing human receptor; inhibition of forskolin-stimulated cAMP for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
    Shown value from
    Zagzoog et al. 2020, Table 2
    Emax
    68.0 ± 2.4%
  • Δ⁹-THC (Tetrahydrocannabinol)Agonistother reports differ250 nMBanister et al. 2015
    Assay
    mouse AtT-20 cells stably expressing human CB1, FLIPR membrane-potential/GIRK assay
    Shown value from
    Banister et al. 2015, Table 1
    Emax
    51.0 ± 3.0%

    This is the best-supported value. Other reports differ. 8 reports in all, 6.0–470 nM.

  • Cannabinol (CBN)Agonist307 nMHusni et al. 2014
    Assay
    HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
    Shown value from
    Husni et al. 2014, Table 1
  • Cannabidiol (CBD)Agonist1469 nMHusni et al. 2014
    Assay
    HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
    Shown value from
    Husni et al. 2014, Table 1
  • Δ⁸-THC (Tetrahydrocannabinol)Agonist5820 nMHusni et al. 2014
    Assay
    HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
    Shown value from
    Husni et al. 2014, Table 1

Mouse

2 measurements

Rat

3 measurements
  • HU-210Agonist0.55 nMGriffin et al. 1998
    Assay
    rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
    Shown value from
    Griffin et al. 1998, Table 2
    Emax
    140.0%
  • CP 55,940Agonist18 nMGriffin et al. 1998
    Assay
    rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
    Shown value from
    Griffin et al. 1998, Table 2
    Emax
    114.0%
  • WIN 55,212-2Agonist151 nMGriffin et al. 1998
    Assay
    rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
    Shown value from
    Griffin et al. 1998, Table 2
    Emax
    156.0%

Unspecified

3 measurements
  • HU-210Agonist0.04 nMRhee et al. 1997
    Assay
    cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
    Shown value from
    Rhee et al. 1997, Table 1
  • Δ⁹-THC (Tetrahydrocannabinol)Agonist11 nMRhee et al. 1997
    Assay
    cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
    Shown value from
    Rhee et al. 1997, Table 1
  • Cannabinol (CBN)Agonist120 nMRhee et al. 1997
    Assay
    cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
    Shown value from
    Rhee et al. 1997, Table 1

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.